Friday, September 29, 2017 4:42:54 PM
GW Pharma slips 15% premarket on Zogenix's successful late-stage study of ZX008 in Dravet
Sep. 29, 2017 7:48 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor
GW Pharmaceuticals (NASDAQ:GWPH) is down 15% premarket, albeit on only 779 shares, in apparent response to Zogenix's announcement of positive Phase 3 results for Dravet syndrome candidate ZX008.
GW's late-stage candidate for Dravet is Epidiolex (cannabidiol).
Previously: Zogenix's lead candidate ZX008 successful in late-stage Dravet study (Sept. 29)
Previously: GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome (April 21, 2015)
https://seekingalpha.com/news/3298365-gw-pharma-slips-15-percent-premarket-zogenixs-successful-late-stage-study-zx008-dravet
I dislike linking Seeking Alpha articles but this one seems to be dead on.
Know What You Own. My posts should not be construed as investment advice.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM